Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade

Terry, Stéphane; Dalban, Cécile; Rioux-Leclercq, Nathalie; Adam, Julien; Meylan, Maxime; Buart, Stéphanie; Bougoüin, Antoine; Lespagnol, Alexandra; Dugay, Frédéric; Colina Moreno, Irelka; Lacroix, Guillaume; B. Lorens, James; Gausdal, Gro; H. Fridman, Wolf; Mami-Chouaib, Fathia; Chaput, Nathalie; Beuselinck, Benoit; Chabaud, Sylvie; Barros-Monteiro, Janice; Vano, Yann; Escudier, Bernard; Sautès-Fridman, Catherine; Albiges, Laurence; Chouaib, Salem

doi:10.1158/1078-0432.ccr-21-0972

Public

Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade

Published in Clinical Cancer Research • Aug 18, 2021

Authors:

Stéphane Terry

Cécile Dalban

Nathalie Rioux-Leclercq

Abstract

PURPOSE: A minority of patients currently respond to single-agent immune-checkpoint blockade (ICB), and strategies to increase response rates are urgently needed. AXL is a receptor tyrosine kinase commonly associated with drug resistance and poor prognosis in many cancer types, including in clear-ce...

Subject

Blockade

Medicine

Renal cell carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!